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Abstract
Background: Thoroughly understanding the temporal associations between cognitive and functional dimensions
along the dementia process is fundamental to define preventive measures likely to delay the disease’s onset. This
work aimed to finely describe the trajectories of cognitive and functional declines, and assess their dynamic
bidirectional relationships among subjects at different stages of the dementia process.
Methods: We leveraged extensive repeated data of cognition and functional dependency from the French prospective
COGICARE study, designed to better characterize the natural history of cognitive and functional declines around dementia
diagnosis. Cognition was measured by the Mini-Mental State Examination, the Isaacs Set Test for verbal fluency, the Benton
Visual Retention Test for visuo-spatial memory, and Trail Making Test Part B for executive functioning. Functional dependency
was measured by basic and instrumental activities of daily living. The study included 102 cognitively normal, 123 mildly
cognitively impaired, and 72 dementia cases with a median of 5 repeated visits over up to 57months. We used a dynamic
causal model which addresses the two essential issues in temporal associations assessment: focusing on intra-individual
change and accounting for time.
Results: Better cognitive abilities were associated with lower subsequent decline of the functional level among the three
clinical stages with an intensification over time but no reciprocity of the association whatever the clinical status.
Conclusion: This work confirms that the progressive functional dependency could be induced by cognitive impairment.
Subjects identified as early as possible with clinically significant cognitive impairments could benefit from preventive
measures before the deterioration of activities of daily living and the appearance of dementia clinical signs.
Keywords: Activities of daily living, Cognitive aging, Mini-Mental State Examination, Temporal association, Causality,
Dementia
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Background
There is now evidence that the pathophysiological
process of Alzheimer’s disease (AD) begins decades be-
fore the appearance of clinical signs of dementia [1–4].
AD’s preclinical stages may constitute a critical window
to define and implement early preventive measures likely
to delay the disease’s onset or magnitudes of symptoms.
Thoroughly describing the multiple dimensions, mainly
cognitive and functional ones, all along the complex AD
process, is consequently fundamental. However, longitu-
dinal studies in this field were mainly limited to one di-
mension at a time ignoring the possible inter-
relationships with others. Yet, investigating how the dif-
ferent dimensions interplay over time at distinct clinical
stages could be a key to better understand the AD
pathological cascade and prioritize interventions.
Uncertainties remain in particular on the temporal re-
lationships between cognitive and functional declines.
Subjects with initial clinical presentation of AD have
been described with cognitive deficits and no evident
limitations in activities of daily living (ADL) that seem to
appear later in the disease process [5]. Correlation be-
tween cognition and function has been shown to in-
crease as AD patients progressed from preclinical to
moderate dementia [6]. Few studies formally assessed
the temporal relationships between patterns of cognitive
and functional declines and potential differences in their
joint evolution along the AD continuum [7–9]. These
results suggest that cognitive decline precedes and pre-
dicts subsequent functional impairment assessed not-
ably, in mild cognitive impairment (MCI), by the ability
to perform ADL. Functional decline has also been sug-
gested as a predictor of both cognitive decline (but only
intermittently and not in incident AD cases) [10] and
conversion from MCI to AD [11].
Since longitudinal processes are likely to vary between
individuals and to change over time, two major aspects
have to be taken into account when investigating tem-
poral relationships [12]. First, time is central and associ-
ation assessment should be unrelated to the visit
schedule. Second, the interest should be in the intra-
individual change rather than the inter-individual differ-
ences. Indeed, from a causal perspective, the goal is to
understand how the system changes as time goes on,
and what factors influence the future individual change
[13]. By relying on autoregressive and cross-lagged
models (ARCL), the rare studies investigating reciprocal
temporal dependencies between cognition and func-
tional dimensions over time [7, 9, 10] did not account
for these two major elements [12]. They considered
inter-individual differences between successive levels of
variables at observed visit times, thus not targeting intra-
individual changes, limiting the interpretation to the visit
schedule of the study, and possibly inducing spurious
associations if sparse [14]. With cognitive and functional
dimensions being measured by scores with ceiling/floor
effects or unequal interval scaling [15], a third aspect to
take into account is the departure from normality which
can induce biased estimates if not properly taken into
account [16].
In the current study, we aimed to finely describe the tra-
jectories of both cognitive and functional declines, and as-
sess their dynamic bidirectional relationships among
subjects with normal aging, MCI or AD participating in a
French cohort study, the natural history of COGnitive de-
cline, and the need of CARE in the elderly (COGICARE)
study. We applied for that a dynamic multivariate causal
model [17] that overcomes the major methodological req-
uisites to assess temporal associations.
Methods
The COGICARE study
The current study analyses the data from COGICARE
which is a sub-study of the Three-City (3C) study in
Montpellier and Bordeaux centers. COGICARE was de-
signed to better characterize the natural history of cogni-
tive and functional declines around dementia diagnosis
through an extensive follow-up of subjects at three dif-
ferent stages: AD, MCI, or cognitively normal (CN). The
study protocols of the 3C and COGICARE studies were
approved by the Ethics Committee of the University
Hospital of Bicêtre and Sud-Méditerranée III (France)
and written informed consent was obtained for each
participant.
The 3C study is a community-living cohort of 9294 el-
ders (≥ 65 years of age) randomly recruited from the
electoral rolls of three French cities (Bordeaux, Dijon,
and Montpellier) between 1999 and 2001 [18]. Standard-
ized examinations including face-to-face interviews and
cognitive and functional assessments (in a medical cen-
ter or at home) took place at inclusion and then every
2–3 years (i.e., after 2, 4, 7, 10, 12, and 14 years of
follow-up). AD incident cases diagnosis was based on an
examination by a neurologist of all participants in Mont-
pellier and of participants suspected of having dementia
(based mainly on their clinical, cognitive, or functional
assessments) in Bordeaux. An adjudication panel of in-
dependent neurologists reviewed all the existing infor-
mation to confirm the diagnosis of dementia according
to the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (DSM-IV) [19], and its etiology. AD
was classified according to the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders As-
sociation (NINCDS/ADRDA) criteria [20]. MCI was de-
fined as (details in Web appendix 1) (i) an alteration of
verbal episodic memory (i.e., a free recall score < 17 and
a total recall score < 40) [21] on the Free and Cued
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Selective Reminding Test (FCSRT) [22] and (ii) partial
or total limitation in their abilities to perform at least
two of four Instrumental Activities of Daily Living
(IADL) [23].
The following were eligible to enter the COGICARE
sub-study: (1) AD incident cases from Bordeaux and
Montpellier centers diagnosed at the 3C 7- or 9-year
follow-up and non-demented at the last visit preceding
the AD diagnosis. Each incident AD case was theoretic-
ally matched to one control considered as cognitively
normal (CN) from the pool of participants free of both
dementia and MCI according to sex, age (+/−2.5 years),
and examination date (within the interval of 45 days be-
fore or after the diagnosis date of their matched AD
case); (2) participants who fulfilled criteria for MCI at
the 3C 9-year follow-up.
Of the 4363 participants included in the Bordeaux’s
and Montpellier’s centers, 2751 and 2409 were still
followed at the 3C 7- and 9-year follow-up, respectively.
Among all incident AD cases at the 7- (n = 133) and 9-
year (n = 114) follow-up, 176 were included in COGI-
CARE (participation rate: 71%). Furthermore, 166 MCI
identified at the 3C 9-year follow-up were included. A
total of 125 matched CN controls were included. The
467 COGICARE participants (AD, MCI, or CN), under-
went cognitive and functional assessments every 6
months from the 3C 9-year follow-up (thereafter consid-
ered as baseline) and during 18–24 months and then
underwent their planned 3C follow-ups.
Cognitive and functional assessments
Three cognitive tests were intensively administered dur-
ing COGICARE follow-up. The global cognitive function
was assessed using the face-to-face 30-item Mini-
Mental-State-Examination (MMSE) [24] for AD and
MCI, and the telephonic 25-item MMSE for CN. Tele-
phonic 25-item MMSE scores were rescaled so that all
MMSE scores ranged from 0 (severe impairment) to 30
(no impairment). The verbal fluency was assessed by the
Isaacs Set Test (IST) truncated at 30 s [25] which was ei-
ther administered face-to-face for AD and MCI or by
telephone for the CN. Its range was 0 to 82. The visuo-
spatial memory was assessed by the Benton Visual Re-
tention Test (BVRT) [26] (range 0–15) during face-to-
face interviews for AD and MCI. In addition, we consid-
ered the Trail Making Test Part B (TMT-B) [27] admin-
istered only during the 3C visits (twice during this study
period) in order to include a measure of executive func-
tioning to the cognitive level definition. The score was
the number of correct moves per minute.
Functional dependency was assessed by the limitation in
basic ADL (BADL) scale [28] and Instrumental ADL
(IADL) scale [23] during face-to-face (for AD and MCI)
and telephonic interviews (for CN). A total of 5 BADL
(bathing, dressing, toileting, eating, and transferring) and 4
IADL (telephone use, transportation, self-administration
of medication, finances) were considered [29], each one
on a 3-point scale as having no limitation, partial limita-
tion, or total limitation (coded 0, 1, and 2 respectively) in
performing the task. Following a previous work that
showed a continuum in IADL and BADL [30], we consid-
ered the total sumscore of IADL and BADL which ranged
from 0 to18.
Study sample within COGICARE
From the 467 participants of the COGICARE study, we
excluded the individuals with no repeated cognitive or
functional measures during the 57 months of follow-up
considered for the present study, and with incomplete
information on potential confounders (Flowchart in
Web Figure 1). Potential confounders were age at base-
line (3C 9-year follow-up) in 5 categories chosen at the
quintiles of the distribution (≤ 79.1 as the reference
class, 79.1–82.0, 82.0–84.5, 84.5–87.7, ≥ 87.7), sex, bin-
ary educational level (lower/equal to primary school ver-
sus higher than primary school), and Apolipoprotein E
(apoE) ε4 status (at least one ε4 allele versus none). The
final study sample included 297 individuals.
Statistical analysis
Trajectories of cognitive and functional declines and
their temporal reciprocal relationships according to the
clinical status (AD, MCI, CN) were assessed using a
multivariate latent process model [17]. The theoretical
graph of the model is specified in Fig. 1.
The model describes the trajectories and inter-
dependencies over time of the cognitive functioning and
functional dependency, defined as two latent processes.
Cognitive process was measured by MMSE, IST, BVRT,
and TMT-B while functional process was measured by
the BADL-IADL sum score. In order to correct for its
departure from normality and ceiling/floor effect, each
observed marker was linked to its underlying latent
process using a marker-specific parameterized link func-
tion approximated by quadratic I-splines with two in-
ternal knots chosen at the quartiles for the MMSE, IST,
BVRT, and TMT-B, and one internal knot at the median
for the limitation score [31]. The latent processes were
standardized (mean 0, standard deviation 1) at baseline
in the reference category (CN men with a higher educa-
tional level and less than 79.1 years old at baseline).
Thus, in the results section, a one-unit change of cogni-
tion or functional dependency always corresponds to the
residual standard deviation of the dimension at baseline
after adjustment for age, sex, age, and clinical stage.
The longitudinal model for the cognitive and func-
tional latent trajectories was split in two subparts to ex-
hibit the temporal relationships. Both parts accounted
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for intra-individual correlation and missing at random
mechanism (as based on the mixed model theory [32]):
– The initial levels of cognitive ability and functional
dependency were regressed on the stage of the
disease, age, apoE4 status, gender, education, the
interaction between education and stage, and an
individual random intercept.
– The changes over time of cognitive ability and
functional dependency were described over a finely
discretized time of 3 months unrelated to the visit
process. The change between t and t + 3months
was regressed on the same covariates as initial levels,
an individual random effect, and the level of
cognitive ability and functional dependency at time
t. The effect of the level of cognitive ability and
functional dependency on each other was different
by stage and could vary over time to precisely
explore their inter-relations, and especially potential
changes in these relationships over time. Further de-
tails on the dynamic model specification are given in
Web Appendix 2.
Statistical analyses were done with R software and the
dynamic model was fitted using CInLPN R package
available at https://github.com/bachirtadde/CInLPN. Re-
ported P values are from two-sided Wald tests.
Results
Sample description
The study sample included 102 CN (34.3%), 123 were
MCI (41.4%), and 72 were AD (24.3%). AD subjects (me-
dian age 84.4 years) were slightly older than MCI (82.0
years) and CN (83.4 years) at inclusion (Table 1). Two
third of the sample were women with slight differences
over groups (65.3%, 58.5%, and 67.6% for AD, MCI, and
CN, respectively). MCI and AD subjects had a lower
educational level compared to CN. Subjects with AD
were more frequently APOE ε4 carriers than CN (36.1%
vs 14.7%). The percentage of individuals with no IADL
and BADL limitations at baseline gradually decreased
between CN, MCI, and AD, and MCI and AD had lower
cognitive scores than CN.
The 170 excluded subjects (see flowchart in Web Fig-
ure 1) were more likely AD (61.2% AD, 13.5% MCI,
25.3% CN). They were slightly older (median age: 86.5)
and more likely to be women (72.9%) than included sub-
jects but comparable regarding their education level and
APOE ε4 status.
Fig. 1 Theoretical graph of the dynamic causal model
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Table 1 Characteristics of participants at baseline (n = 297), COGICARE study
CN MCI AD All
(N = 102) (N = 123) (N = 72) (N = 297)
Age in years: median (min–max) 83.4 (75.6–92.8) 82.0 (74.2–95.2) 84.4 (76.0–93.5) 82.9 (74.2–95.2)
Male sex (%) 32.35 41.46 34.72 36.70
Education level higher than primary school (%) 77.45 65.85 62.50 69.02
ApoE4 carriers (%) 14.71 13.82 36.11 19.53
Limitation in activities of daily living (%):
Bathing
No limitation 96.08 95.93 66.67 88.89
Partial limitation 1.96 2.44 16.67 5.72
Total limitation 1.96 1.63 16.67 5.39
Dressing
No limitation 96.08 97.56 73.61 91.25
Partial limitation 0.98 1.63 13.89 4.38
Total Limitation 2.94 0.81 12.50 4.38
Toileting
No limitation 100.00 99.19 95.83 98.65
Partial limitation 0.00 0.00 4.17 1.01
Total limitation 0.00 0.81 0.00 0.34
Transfering
No limitation 99.02 99.19 94.44 97.98
Partial limitation 0.98 0.81 5.56 2.02
Total limitation 0.00 0.00 0.00 0.00
Eating
No limitation 99.02 100.00 95.83 98.65
Partial limitation 0.98 0.00 4.17 1.35
Total limitation 0.00 0.00 0.00 0.00
Limitation in instrumental activities of daily living (%):
Telephone use
No limitation 100.00 95.12 56.94 87.54
Partial limitation 0.00 4.88 36.11 10.77
Total limitation 0.00 0.00 6.94 1.68
Shopping
No limitation 78.43 77.24 36.11 67.68
Partial limitation 13.73 19.51 26.39 19.19
Total limitation 7.84 3.25 37.50 13.13
Transportation
No limitation 79.41 83.74 44.44 72.73
Partial limitation 19.61 15.45 48.61 24.92
Total limitation 0.98 0.81 6.94 2.36
Medication
No limitation 99.02 95.12 48.61 85.19
Partial limitation 0.00 4.07 25.00 7.74
Total limitation 0.98 0.81 26.39 7.07
Finances
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Table 1 Characteristics of participants at baseline (n = 297), COGICARE study (Continued)
CN MCI AD All
(N = 102) (N = 123) (N = 72) (N = 297)
No limitation 89.22 86.99 41.67 76.77
Partial limitation 10.78 11.38 26.39 14.81
Total limitation 0.00 1.63 31.94 8.42
Cognitive scores: median (min–max)
MMSE 28 (17–30) 27 (20–30) 23 (11–28) 27 (11–30)
IST 45 (22–82) 39 20–61) 29 (12–62) 39 (12–82)
BVRT 12 (6–15) 11 (5–15) 9 (5–14) 11 (5–15)
TMT-B 26.5 (3.0–60.0) 21.3 (0.5–62.6) 7.3 (0.7–40.0) 20.0 (0.5–62.6)
Limitation score: median (min–max) 0 (0–7) 0 (0–14) 3 (0–13) 0 (0–14)
Number of measures by subject over follow-up: median (min–max)
MMSE 5 (2–6) 5 (2–7) 4 (1–7) 5 (1–7)
IST 4 (1–6) 5 (1–7) 4 (1–7) 4 (1–7)
BVRT 2 (1–4) 5 (2–6) 3 (1–7) 3 (1–7)
TMT-B 2 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Limitations 5 (2–6) 5 (2–7) 5 (2–7) 5 (2–7)
Fig. 2 Predicted mean trajectories over time (plain line) and associated 95% confidence intervals (shades) of the underlying cognitive ability and
functional dependency according to the clinical stage (CN, MCI, and AD) and education; trajectories are displayed for non-APOE ε4 carriers; male
sex and aged between 82.60 and 85.12. Ninety-five percent confidence intervals were obtained using a Monte Carlo method with 2000 draws
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The sample comprised a total of 3974 and 1388 re-
peated measures of cognition (through the 4 scores) and
function, respectively. The median number of visits per
participant was 5 for all groups. Web Table 1 and Web
Figure 2 further describe the number of measurements
available by clinical stage and 3-month steps and the ob-
served individual marker trajectories.
Cognitive and functional trajectories
The mean predicted trajectories of cognition and function
showed a gradual progression from normal to AD stage with
differences according to education (Fig. 2). Estimations from
the dynamic model for cognitive and functional trajectories
are reported in Table 2 for the baseline levels and in Table 3
for the rates of change and further described below. The as-
sociation between observed markers and the underlying di-
mensions highlighted the curvilinear nature of the markers
and notably confirmed the ceiling effect of MMSE and the
floor effect of TMT-B (See Web Figure 3). The adequacy of
the model to the data was very good (see Web Figure 4 for
the comparison of predictions with observations).
Association with baseline cognitive and functional levels
A gradient in baseline cognitive and functional abilities was
observed according to the clinical stage after adjustment for
other potential confounding factors, with slight differences
according to education. Participants with an educational level
higher than primary school had systematically a higher cog-
nitive level in mean compared to low educated participants
with no substantial differences across groups (mean differ-
ence in the latent dimension scale (MD) = − 0.868, 95% con-
fidence interval (95%CI) =− 1.308, − 0.429, P = 0.0001 for
CN; MD = − 0.649, 95%CI = − 1.013, − 0.285, P = 0.0005 for
MCI; and MD = − 0.695, 95%CI = − 1.178, − 0.211, P =
0.005 for AD). For functional dependency, differences ac-
cording to education were only observed among AD sub-
jects, lower educated AD subjects having higher limitations
than higher educated AD subjects (MD = 0.838, 95%CI =
0.237, 1.439, P = 0.006). Adjusted for clinical stage and other
potential confounding factors, there were no differences in
cognition according to APOE ε4 status (p = 0.954) and gen-
der (p = 0.903). However, APOE ε4 carriers tended to have a
better functional ability (MD = − 0.355, 95%CI = −
Table 2 Estimated associations with the underlying cognitive ability and functional dependency level at baseline (n = 297),
COGICARE study
Cognitive ability at baseline Functional dependency at baseline
Coefficient* 95% confidence interval Coefficient* 95% confidence interval
Clinical stage by education level
Higher than primary school
CN 0 - 0 -
MCI − 0.882 − 1.284 − 0.480 0.171 − 0.275 0.617
AD − 2.878 − 3.419 − 2.337 1.974 1.415 2.532
Lower or equal to primary school
CN − 0.868 − 1.308 − 0.429 0.188 − 0.417 0.793
MCI − 1.531 − 2.044 − 1.018 0.089 − 0.412 0.591
AD − 3.572 − 4.219 − 2.926 2.811 2.105 3.518
Age at baseline
≤ 79.1 0 - 0 -
79.1–82.0 − 0.284 − 0.680 0.113 0.069 − 0.396 0.534
82.0–84.5 − 0.461 − 0.870 − 0.053 0.304 − 0.167 0.775
84.5–87.7 − 0.288 − 0.691 0.116 0.284 − 0.200 0.767
> 87.7 − 0.754 − 1.146 − 0.362 1.028 0.508 1.549
APOE ε4 carrier
No
Yes − 0.010 − 0.351 0.331 − 0.355 − 0.741 0.031
Sex
Male
Female − 0.016 − 0.270 0.238 0.316 − 0.017 0.650
*One-unit difference corresponds to the standard deviation of the dimension at baseline in the category reference (CN men with a higher educational level and
less than 79.6 years old at baseline)
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0.741,0.0310, P = 0.072) at baseline compared to
non-carriers, and so did men (MD = − 0.316, 95%CI
= − 0.650, 0.017, P = 0.063). Older individuals were
more cognitively and functionally impaired adjusted
for the other factors.
Association with cognitive and functional rates of change
Adjusted for confounding factors, the functional level at
any time t was not significantly associated with the sub-
sequent rate of change in cognitive dimension in any
group (all p> 0.320). In contrast, whatever the clinical
Table 3 Estimated associations with the rate of change of underlying cognitive ability and functional dependency (n = 297),
COGICARE study
Change over time of cognitive ability Change over time of functional dependency
Coefficient* 95% CI Coefficient* 95% CI
Intercept − 0.247 − 0.371 − 0.122 0.201 − 0.370 0.772
Clinical stage
CN 0 - 0 -
MCI 0.176 0.021 0.332 0.194 − 0.223 0.611
AD 0.377 − 0.031 0.785 2.166 0.784 3.549
Age at baseline
≤ 79.6 0 - 0 -
79.60–82.60 − 0.021 − 0.165 0.124 − 0.144 − 0.552 0.264
82.60–85.12 − 0.040 − 0.191 0.110 − 0.091 − 0.508 0.325
85.12–88.34 0.003 − 0.141 0.148 0.175 − 0.248 0.599
> 88.34 0.043 − 0.119 0.204 0.732 0.114 1.349
APOE ε4 carrier
No 0 - 0 -
Yes − 0.017 − 0.139 0.104 − 0.211 − 0.582 0.159
Sex
Male 0 - 0 -
Female 0.061 − 0.036 0.157 0.117 − 0.201 0.436
Education level
> Primary school 0 - 0 -
≤ Primary school 0.239 0.124 0.355 − 0.471 − 0.828 − 0.114
Current functional level**
CN − 0.086 − 0.254 0.082 − 1.105 − 1.943 − 0.267
MCI − 0.010 − 0.141 0.122 − 0.643 − 1.247 − 0.038
AD − 0.032 − 0.160 0.096 − 0.877 − 1.484 − 0.269
CN × time 0.032 − 0.035 0.100
MCI × time − 0.008 − 0.057 0.042
AD × time 0.033 − 0.003 0.069
Current cognitive level**
CN 0.154 0.052 0.255 − 0.403 − 0.783 − 0.023
MCI 0.185 0.081 0.290 − 0.307 − 0.609 − 0.006
AD 0.235 0.130 0.340 − − 0.342 − 0.601 − − 0.083
CN × time − 0.281 − 0.468 − 0.095
MCI × time − 0.215 − 0.413 − 0.018
AD × time − 0.043 − 0.099 0.014
*One unit corresponds to an annual change of the same size as one standard deviation of the dimension at baseline in the reference category (CN men with a
higher educational level and less than 79.6 years old at baseline)
**One unit corresponds to the standard deviation of the dimension at baseline in the reference category (CN men with a higher educational level and less than
79.6 years old at baseline)
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stage, the cognitive level significantly affected the subse-
quent rate of change of functional dependency after ad-
justment on potential confounding factors (in all groups:
p< 0.045 at baseline, p< 0.009 at 2 years, p< 0.012 at 4
years). As illustrated in Fig. 3, higher cognitive abilities
at any given time were systematically associated with a
lower subsequent change in functional limitations with
an intensification of the association over time for CN
subjects and to a lesser extent for MCI (and even lesser
extent for AD). This means that the benefit of better
cognitive abilities on the change of limitation was larger
and larger as the time spent in the cohort increased. The
annual change in functional limitations was reduced by
0.403 (95%CI = 0.023, 0.783, P = 0.037), 0.966 (95%CI =
0.355, 1.576, P = 0.002), and 1.529 (95%CI = 0.591,
2.466, P = 0.001) for a one-unit increase of current cog-
nition in CN subjects after 0, 2, and 4 years in the co-
hort, respectively. It was reduced by 0.307 (95%CI =
0.006, 0.609, P = 0.045), 0.738 (95%CI = 0.184, 1.293, P
= 0.009), and 1.169 (95%CI = 0.255, 2.084, P = 0.012) for
a one-unit increase of current cognition in MCI subjects
after 0, 2, and 4 years, respectively. It was reduced by
0.342 (95%CI = 0.083, 0.601, P = 0.010), 0.427 (95%CI =
0.118,0.736, P = 0.007), and 0.512 (95%CI = 0.126, 0.899,
P = 0.009) for a one-unit increase of current cognition
in AD subjects after 0, 2, and 4 years in the cohort,
respectively.
The size of these temporal associations can be com-
pared with others. For instance, for the same current
cognitive level, and the same other confounding factors,
the annual change of functional limitations was reduced
by 1.105 (95%CI = 0.267, 1.943, p = 0.010), 0.643 (95%CI
= 0.038, 1.247, p = 0.037), and 0.877 (95%CI = 0.269,
1.484, p = 0.005) for a one-unit increase of current func-
tional limitation in CN, MCI, and AD, respectively. The
annual increase in functional limitations was also less
pronounced for low educated subjects compared to
higher educated subjects with a constant mean differ-
ence of − 0.471 (95%CI = − 0.828, − 0.114, P = 0.010).
Adjusted for current cognitive and functional levels
and other confounding factors, there was no residual as-
sociation with an annual change of cognition or limita-
tion for gender, APOE ε4, and age except for the oldest
(> 88.3 years old) who had a higher increase of functional
dependency than younger participants. There was also a
residual association of clinical status with functional
change, AD individuals having a much higher functional
annual change (MD = 2.166, 95%CI = 0.784, 3.549, P <
0.002) than CN and MCI.
Discussion
Leveraging longitudinal cohort data and exploiting a dy-
namic statistical model dedicated to the evaluation of
temporal associations, this work allows understanding
the cognitive and functional trajectories over time along
the AD continuum, from normal cognitive aging to MCI
and AD, and assesses the temporal relationships between
cognitive and functional dimensions. Our study showed
that better cognitive abilities were associated with a
lower subsequent decline of the functional level among
CN, MCI, and AD, but with no reciprocity whatever the
clinical stage. We adjusted on main confounders identi-
fied in cognitive aging studies but cannot exclude re-
sidual confounding in these relationships.
Our results are consistent with part of the few studies
that explored the potential reciprocal causal-effect be-
tween cognitive decline and functional impairment and
showed that in MCI subjects or non-demented
community-dwelling older persons the cognitive impair-
ment preceded and predicted subsequent functional
Fig. 3 Estimated trajectory of temporal influence (and associated 95%CI) of the cognitive level on the subsequent functional dependency change
according to the time in the cohort by clinical status (CN, MCI, and AD). The reported temporal influence corresponds to the difference in the
annual change of functional dependency for a one-unit increase of the current cognitive level
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decline but functional impairment did not predict cogni-
tive decline [7–9, 33, 34]. Although Zahodne et al. [10]
also concluded to a main causal effect of the cognitive
impairment on the functional decline, they reported
more mixed findings with a causal effect of the func-
tional decline on the cognitive impairment also observed
at a few times in non-demented elders and prevalent AD
but not in incident AD. Several other studies have not
formally explored the dynamic bi-directional association,
but rather described the trajectories of cognitive and
functional abilities and compared the shape of the de-
clines in the pre-dementia phase. They identified that
the decline in cognitive performances (observed first in
measures of semantic memory and conceptual forma-
tion, and then in more global cognitive functioning) pre-
ceded the increase in dependency in IADL and in BADL
[1, 35].
From a methodological point of view, differences in
the literature results could first be attributable to hetero-
geneity in the scales used to assess cognitive and func-
tional dimensions, some functional scales including for
instance a social dimension. Second, previous works
used ARCL models which focus on (i) determinants of
inter-individual differences over time rather than deter-
minants of intra-individual changes [12, 13] and (ii) dif-
ferences between observed visits in the study rather than
differences in continuous [12–14] or finely discretized
[17] time which are yet necessary for causal interpreta-
tions. The use of ARCL models makes previous results
strongly dependent on the visit schedule, possibly too
sparse for causal interpretation, and different from one
study to the other so that comparisons are challenging.
It also assumes that processes do not substantially
change over time at the individual level which is very
unlikely. In our work, we circumvented these limits by
exploring associations with the subsequent individual
rate of change of each dimension and retrieving associ-
ation over a 3-month period which is unrelated to the
visit schedule and very small compared to the AD
process timescale. By relying on the mixed model theory,
the method naturally handled intermittent and mono-
tonic missing data under the missing at random mech-
anism [36]. We also considered that the temporal
relationships may evolve between CN, MCI, and AD,
and over time within each group, thus allowing the iden-
tification of specific time windows where the cognitive/
functional dimensions could have a more important in-
fluence on the evolution of the other. We underlined
that the cognitive latent dimension influenced the func-
tional change at each stage of the disease and at each
time window of interest. However, the influence of high
cognitive abilities in maintaining the functional abilities
increased over time, particularly in cognitively normal
and MCI subjects.
A major strength of this work is the repeated longitu-
dinal data collected in the COGICARE study. Exploring
subtle changes in the dynamic of cognitive and func-
tional dimensions was made possible by the regular
follow-up of elders along the disease process. In this
study, the MCI and AD groups were precisely defined.
Subjects with AD were identified through an active
screening and confirmed by an independent experts
committee. The potential of a misclassification bias is
thus minimized. The threshold used to identify MCI has
also been shown to discriminate MCI who will develop
AD from MCI non-converters [21]. Targeting these sub-
jects offered the opportunity to better characterize the
prodromal period of AD. When exploring temporal rela-
tionships, the number of repeated measures is also a
critical issue. The median number of visits per subject in
our study was 5 in all groups both for the cognitive and
functional dimensions. It is particularly valuable for AD
as the disease is often closely associated with attrition
that can potentially introduce bias in the results and
lower the possibility to assess the dynamic of processes.
Finally, the cognitive dimension was defined from an ex-
tensive battery of cognitive tests including global func-
tioning, visuo-spatial memory, verbal fluency, and
executive functioning, domains particularly central in
cerebral aging. The definition of a general latent cogni-
tive factor using these specific domains had been previ-
ously validated by the authors [37].
Limitations
This study has some limitations. First, some psychomet-
ric tests (BVRT for CN and TMT-B for all groups) were
only assessed during the 3C interviews. Considering
TMT-B substantially reduced the size of the sample (112
participants did not have any TMT-B evaluation). How-
ever, it was critical that the cognitive dimension included
an assessment of executive functioning given the robust
relationship between instrumental activities of daily liv-
ing and tests of executive function repeatedly identified
in the literature (e.g., [38]).
Second, at COGICARE visits, MMSE and IST scores
resulted from telephonic interviews among controls and
from face-to-face interviews in MCI and AD subjects.
However, it has been shown that telephonic version of
MMSE provides reliable results [39]. In addition, the
shape of the latent cognitive process trajectories over
time among controls seems coherent with previous stud-
ies [1, 40]. Functional dependency was assessed through
a summary score of 4 instrumental activities of daily liv-
ing and 5 basic activities of daily living following previ-
ous works that showed a continuum of degradation in
these items [29, 30]. However, by focusing on (instru-
mental) activities of daily living, we might have missed
very early changes in functional dependency. Finally, we
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considered that data were missing at random and we did
not take into account the possible changes of status over
time. Yet, by the end of the follow-up, 26 of the 123
MCI had become AD, and 24/8 of the 102 controls had
become MCI/AD. Therefore results must be interpreted
for groups of subjects initially healthy, MCI or AD.
Conclusion
The approach we used provides valuable information on the
dynamic co-evolution of the cognitive and function dimen-
sions along the AD continuum. This work supports the hy-
pothesis that cognitive performances contribute to maintain
functional abilities whether subjects are cognitively normal
or in the pathological process of cognitive decline. As stated
in a recent FDA report [41], such a result is an essential ar-
gument to reinforce persuasiveness of the clinical trials iden-
tifying treatment effect on cognitive functioning. We
highlighted that the benefit of cognitive performances in
maintaining functional abilities increased over time when
subjects were cognitively normal or at the beginning of the
pathological process (MCI) but not at later stages (AD) when
the severity of the disease is probably so high that function
cannot be maintained. In the absence of a cure for AD, a piv-
otal challenge is to maintain a good quality of life for future
AD as long as possible without overwhelming functional
abilities. Identifying subjects with significant cognitive impair-
ments as early as possible is consequently crucial so that they
can benefit from preventive measures before the appearance
of AD clinical signs.
Supplementary Information




Computer time was provided by the computing facilities MCIA (Mésocentre
de Calcul Intensif Aquitain) at the Université de Bordeaux and the Université
de Pau et des Pays de l’Adour.
Authors’ contributions
All authors contributed to the study conception and design. Acquisition of
the data was performed by Catherine Helmer and Claudine Berr. Statistical
analyses were performed by Sophie Carles, Bachirou Taddé and Cécile
Proust-Lima. All the authors contributed to the interpretation of the results.
The first draft of the manuscript was written by Sophie Carles and Cécile
Proust-Lima, and all authors commented on previous versions of the manu-
script. All authors read and approved the final manuscript.
Funding
This study was funded by the French National Research Agency [grant ANR-
15-CE37-0002 for the SMALA project, grant ANR-07-LVIE-003 for the COGI-
CARE project].
Availability of data and materials
Anonymized data will be shared by reasonable request to the 3C scientific
committee. Scripts for replicating the analyses can be sent on demand.
Declarations
Ethics approval and consent to participate
The study protocols of the 3C and COGICARE studies used in this work were
approved by the Ethics Committee of the University Hospital of Bicêtre and





No conflict of interest or competing interests.
Author details
1Institute for Neurosciences of Montpellier INM, Univ. Montpellier, INSERM,
F-34091 Montpellier, France. 2Univ. Bordeaux, INSERM, BPH, U1219, F-33000
Bordeaux, France.
Received: 13 November 2020 Accepted: 9 August 2021
References
1. Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P,
et al. Prodromal Alzheimer’s disease: successive emergence of the clinical
symptoms. Ann Neurol. 2008;64(5):492–8. https://doi.org/10.1002/ana.21509.
2. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic
process in Alzheimer disease: age categories from 1 to 100 years. J
Neuropathol Exp Neurol. 2011;70(11):960–9. https://doi.org/10.1097/NEN.
0b013e318232a379.
3. Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C,
et al. The Paquid epidemiological program on brain ageing. Neuroepidemiology.
1992;11(Suppl 1):14–8. https://doi.org/10.1159/000110955.
4. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders [Internet]. Fifth Edition. Arlington (VA): American
Psychiatric Association; 2013. Available from: https://psychiatryonline.org/
doi/book/10.1176/appi.books.9780890425596
5. Knopman DS. Alzheimer’s Disease and Other Dementias. Goldman’s Cecil
Medicine: Twenty Fourth Edition [Internet]. Elsevier Inc.; 2011 [cited 2020
Sep 17];2274–83. Available from: https://mayoclinic.pure.elsevier.com/en/
publications/alzheimers-disease-and-other-dementias-3
6. Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, et al.
Correlation between Cognition and Function across the Spectrum of
Alzheimer’s Disease. J Prev Alzheimers Dis. 2016;3(3):138–44. https://doi.
org/10.14283/jpad.2016.99.
7. Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen
P Analysis of the Relationship of Cognitive Impairment and Functional
Impairment in Mild Alzheimer’s Disease in EXPEDITION 3. J Prev Alzheimers
Dis [Internet]. 2018 [cited 2020 Sep 17];5:184–7. Available from: https://doi.
org/10.14283/jpad.2018.22, 1, 4
8. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, et al. Cognitive
and functional decline and their relationship in patients with mild
Alzheimer’s dementia. J Alzheimers Dis. 2015;43(3):949–55. https://doi.org/1
0.3233/JAD-140792.
9. Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, et al. Cognitive
Impairment Precedes and Predicts Functional Impairment in Mild
Alzheimer’s Disease. J Alzheimers Dis. 2015;47(1):205–14. https://doi.org/1
0.3233/JAD-142508.
10. Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y. Cognitive declines precede
and predict functional declines in aging and Alzheimer’s disease. PLoS ONE.
2013;8(9):e73645. https://doi.org/10.1371/journal.pone.0073645.
11. Reppermund S, Brodaty H, Crawford JD, Kochan NA, Draper B, Slavin MJ,
et al. Impairment in instrumental activities of daily living with high cognitive
demand is an early marker of mild cognitive impairment: the Sydney
memory and ageing study. Psychological Medicine. 2013;43(11):2437–45.
https://doi.org/10.1017/S003329171200308X.
12. Selig JP, Preacher KJ. Mediation Models for Longitudinal Data in
Developmental Research. Research in Human Development [Internet].
Routledge; 2009 [cited 2020 Sep 17];6:144–64. Available from: https://doi.
org/10.1080/15427600902911247
Carles et al. Alzheimer's Research & Therapy          (2021) 13:148 Page 11 of 12
13. Voelkle MC, Gische C, Driver CC, Lindenberger U. The Role of Time in the
Quest for Understanding Psychological Mechanisms. Multivariate Behav Res.
2018;53(6):782–805. https://doi.org/10.1080/00273171.2018.1496813.
14. Aalen OO, Røysland K, Gran JM, Kouyos R, Lange T. Can we believe the
DAGs? A comment on the relationship between causal DAGs and
mechanisms. Stat Methods Med Res. 2016;25(5):2294–314. https://doi.org/1
0.1177/0962280213520436.
15. Proust-Lima C, Amieva H, Dartigues J-F, Jacqmin-Gadda H. Sensitivity of four
psychometric tests to measure cognitive changes in brain aging-
population-based studies. Am J Epidemiol. 2007;165(3):344–50. https://doi.
org/10.1093/aje/kwk017.
16. Proust-Lima C, Dartigues JF, Jacqmin-Gadda H. Misuse of the linear mixed
model when evaluating risk factors of cognitive decline. Am J Epidemiol.
2011;174(9):1077–88. https://doi.org/10.1093/aje/kwr243.
17. Taddé BO, Jacqmin-Gadda H, Dartigues J-F, Commenges D, Proust-Lima C.
Dynamic modeling of multivariate dimensions and their temporal
relationships using latent processes: Application to Alzheimer’s disease.
Biometrics. 2020;76(3):886–99. https://doi.org/10.1111/biom.13168.
18. 3C Study Group. Vascular factors and risk of dementia: design of the Three-
City Study and baseline characteristics of the study population.
Neuroepidemiology. 2003;22:316–25.
19. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services
Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44. https://doi.
org/10.1212/WNL.34.7.939.
21. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al.
Amnestic syndrome of the medial temporal type identifies prodromal AD: a
longitudinal study. Neurology. 2007;69(19):1859–67. https://doi.org/10.1212/
01.wnl.0000279336.36610.f7.
22. Grober E, Sanders AE, Hall C, Lipton RB. Free and cued selective reminding
identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord.
2010;24(3):284–90. https://doi.org/10.1097/WAD.0b013e3181cfc78b.
23. Lawton MP, Brody EM. Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist. 1969;9(3 Part 1):179–86.
https://doi.org/10.1093/geront/9.3_Part_1.179.
24. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):
189–98. https://doi.org/10.1016/0022-3956(75)90026-6.
25. Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in
old people. Br J Psychiatry. 1973;123(575):467–70. https://doi.org/10.1192/
bjp.123.4.467.
26. Benton AL. Test de rétention visuelle (2e éd.). Paris: les Editions du Centre
de Psychologie Appliquée; 1965.
27. Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain Damage.
Percept Mot Skills [Internet]. SAGE Publications Inc; 1958 [cited 2021 Mar 19];8:271–6.
Available from: https://doi.org/10.2466/pms.1958.8.3.271
28. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in
the Aged: The Index of ADL: A Standardized Measure of Biological and
Psychosocial Function. JAMA [Internet]. American Medical Association; 1963
[cited 2020 Oct 15];185:914–9. Available from: https://jamanetwork.com/
journals/jama/fullarticle/666768
29. Barberger-Gateau P, Rainville C, Letenneur L, Dartigues JF. A hierarchical
model of domains of disablement in the elderly: a longitudinal approach.
Disabil Rehabil. 2000;22(7):308–17. https://doi.org/10.1080/096382800296665.
30. Edjolo A, Proust-Lima C, Delva F, Dartigues J-F, Pérès K. Natural History of
Dependency in The Elderly. A 24-Year Population-Based Study using a
Longitudinal Item Response Theory Model. American Journal of
Epidemiology. 2015;accepted.
31. Proust-Lima C, Amieva H, Jacqmin-Gadda H. Analysis of multivariate mixed
longitudinal data: a flexible latent process approach. Br J Math Stat Psychol.
2013;66(3):470–87. https://doi.org/10.1111/bmsp.12000.
32. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics.
1982;38(4):963–74. https://doi.org/10.2307/2529876.
33. Njegovan V, Hing MM, Mitchell SL, Molnar FJ. The hierarchy of functional
loss associated with cognitive decline in older persons. J Gerontol A Biol Sci
Med Sci. 2001;56(10):M638–43. https://doi.org/10.1093/gerona/56.10.M638.
34. Ishizaki T, Yoshida H, Suzuki T, Watanabe S, Niino N, Ihara K, et al. Effects of
cognitive function on functional decline among community-dwelling non-
disabled older Japanese. Arch Gerontol Geriatr. 2006;42(1):47–58. https://doi.
org/10.1016/j.archger.2005.06.001.
35. Verlinden VJA, van der Geest JN, de Bruijn RFAG, Hofman A, Koudstaal PJ,
Ikram MA. Trajectories of decline in cognition and daily functioning in
preclinical dementia. Alzheimer’s & Dementia. 2016;12(2):144–53. https://doi.
org/10.1016/j.jalz.2015.08.001.
36. Little RJ, Rubin DB. Statistical analysis with missing data. John Wiley & Sons; 2019.
37. Proust-Lima C, Amieva H, Letenneur L, Orgogozo JM, Jacqmin-Gadda H,
Dartigues JF. Gender and education impact on brain aging: a general
cognitive factor approach. Psychol Aging. 2008;23(3):608–20. https://doi.
org/10.1037/a0012838.
38. Szlyk JP, Myers L, Zhang Y, Wetzel L, Shapiro R. Development and
assessment of a neuropsychological battery to aid in predicting driving
performance. J Rehabil Res Dev. 2002;39(4):483–96.
39. Newkirk LA, Kim JM, Thompson JM, Tinklenberg JR, Yesavage JA, Taylor JL.
Validation of a 26-point telephone version of the Mini-Mental State
Examination. Journal of Geriatric Psychiatry and Neurology. 2004;17(2):81–7.
https://doi.org/10.1177/0891988704264534.
40. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C,
Letenneur L, et al. The 9 year cognitive decline before dementia of the
Alzheimer type: a prospective population-based study. Brain. 2005;128(5):
1093–101. https://doi.org/10.1093/brain/awh451.
41. Center for Drug Evaluation and Research. Alzheimer’s Disease: Developing
Drugs for Treatment Guidance for Industy [Internet]. Food and Drug




Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Carles et al. Alzheimer's Research & Therapy          (2021) 13:148 Page 12 of 12
